Journal of Clinical Medicine (Jul 2021)

The Impact of Age on Mortality in Chronic Haemodialysis Population with COVID-19

  • Ander Vergara,
  • Mireia Molina-Van den Bosch,
  • Néstor Toapanta,
  • Andrés Villegas,
  • Luis Sánchez-Cámara,
  • Patricia de Sequera,
  • Joaquín Manrique,
  • Amir Shabaka,
  • Inés Aragoncillo,
  • María Carmen Ruiz,
  • Silvia Benito,
  • Emilio Sánchez,
  • María José Soler

DOI
https://doi.org/10.3390/jcm10143022
Journal volume & issue
Vol. 10, no. 14
p. 3022

Abstract

Read online

Age and chronic kidney disease have been described as mortality risk factors for coronavirus disease 2019 (COVID-19). Currently, an important percentage of patients in haemodialysis are elderly. Herein, we investigated the impact of age on mortality among haemodialysis patients with COVID-19. Data was obtained from the Spanish COVID-19 chronic kidney disease (CKD) Working Group Registry. From 18 March 2020 to 27 August 2020, 930 patients on haemodialysis affected by COVID-19 were included in the Registry. A total of 254 patients were under 65 years old and 676 were 65 years or older (elderly group). Mortality was 25.1% higher (95% CI: 22.2–28.0%) in the elderly as compared to the non-elderly group. Death from COVID-19 was increased 6.2-fold in haemodialysis patients as compared to the mortality in the general population in a similar time frame. In the multivariate Cox regression analysis, age (hazard ratio (HR) 1.59, 95% CI: 1.31–1.93), dyspnea at presentation (HR 1.51, 95% CI: 1.11–2.04), pneumonia (HR 1.74, 95% CI: 1.10–2.73) and admission to hospital (HR 4.00, 95% CI: 1.83–8.70) were identified as independent mortality risk factors in the elderly haemodialysis population. Treatment with glucocorticoids reduced the risk of death (HR 0.68, 95% CI: 0.48–0.96). In conclusion, mortality is dramatically increased in elderly haemodialysis patients with COVID-19. Our results suggest that this high risk population should be prioritized in terms of protection and vaccination.

Keywords